Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion

Heather K Armstrong, Joanna L Gillis, Ian R D Johnson, Zeyad D Nassar, Max Moldovan, Claire Levrier, Martin C Sadowski, Mei Yieng Chin, Emma S Tomlinson Guns, Gerard Tarulli, David J Lynn, Douglas A Brooks, Luke A Selth, Margaret M Centenera, Lisa M Butler

    Research output: Contribution to journalArticlepeer-review

    29 Citations (Scopus)
    27 Downloads (Pure)


    The molecular chaperone Hsp90 is overexpressed in prostate cancer (PCa) and is responsible for the folding, stabilization and maturation of multiple oncoproteins, which are implicated in PCa progression. Compared to first-in-class Hsp90 inhibitors such as 17-allylamino-demethoxygeldanamycin (17-AAG) that were clinically ineffective, second generation inhibitor AUY922 has greater solubility and efficacy. Here, transcriptomic and proteomic analyses of patient-derived PCa explants identified cytoskeletal organization as highly enriched with AUY922 treatment. Validation in PCa cell lines revealed that AUY922 caused marked alterations to cell morphology, and suppressed cell motility and invasion compared to vehicle or 17-AAG, concomitant with dysregulation of key extracellular matrix proteins such as fibronectin (FN1). Interestingly, while the expression of FN1 was increased by AUY922, FN1 secretion was significantly decreased. This resulted in cytosolic accumulation of FN1 protein within late endosomes, suggesting that AUY922 disrupts vesicular secretory trafficking pathways. Depletion of FN1 by siRNA knockdown markedly reduced the invasive capacity of PCa cells, phenocopying AUY922. These results highlight a novel mechanism of action for AUY922 beyond its established effects on cellular mitosis and survival and, furthermore, identifies extracellular matrix cargo delivery as a potential therapeutic target for the treatment of aggressive PCa.

    Original languageEnglish
    Article number2090
    Number of pages14
    JournalScientific Reports
    Issue number1
    Publication statusPublished - 1 Dec 2018


    • molecular chaperone Hsp90
    • prostate cancer
    • AUY922 treatment


    Dive into the research topics of 'Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion'. Together they form a unique fingerprint.

    Cite this